

# MINUTES OF THE SECRETARY OF STATE FOR TRANSPORT'S HONORARY MEDICAL ADVISORY PANEL ON DRIVING AND DISORDERS OF THE CARDIOVASCULAR SYSTEM Meeting held on Thursday 16th March 2023

### **Present:**

### **Panel Members:**

Dr Robert Henderson (Chair)

Dr Kim Rajappan

Mr Andrew Goodwin

Dr Sern Lim

Mr Amar Vara (Lay member)

Mrs Linda Samuels (Lay member)

#### **OBSERVERS:**

Dr John McVicker Director Occupational Health Service, Northern Ireland Dr Sue Stannard Chief Medical Advisor Maritime and Coastguard Agency

Dr Mark Cairns Civil Aviation Authority

## **Expert Guests**

Professor Maria Teresa Tome Esteban Consultant Cardiologist & Professor of Practice Cardiology at

St George's University Hospitals NHS Foundation

Dr Trevor Cleveland Consultant Vascular Interventional Radiologist, Sheffield

Teaching Hospitals NHS Foundation Trust

#### **Ex-officio:**

Dr Nick Jenkins Senior DVLA Doctor

Dr Nerys Lewis Deputy Senior DVLA Doctor

Mrs Keya Nicholas Driver Medical Licensing Policy Lead Mr Dewi Richards Driver Medical Licensing Policy

Mr Richard Davies Service Management

Mrs Sharon Abbott Senior Lead of Business & Customer Support

Mrs Siân Taylor DVLA Panel Coordinator/PA to the Senior DVLA Doctor

Mrs Katy Adams DVLA Panel Coordinator Support





# **SECTION A: INTRODUCTION**

# 1. Apologies for Absence

Apologies were received from:

Dr Douglas Fraser Consultant Cardiologist

Dr Shahid Aziz Consultant Interventional Cardiologist

Dr Ed Bebb Head of Health and Wellbeing, Rail Safety & Standards Board Dr Derek Crinion National Programme Office for Traffic Medicine, Ireland

### 2. CHAIR'S REMARKS

The panel Chair welcomed all attendees and reminded members to ensure their declarations of interest were up to date.

The panel Chair sought clarification with regard to responsibilities around conflicts of interest and DVLA advised that the responsibility to identify conflicts of interest resides with the chair whilst decisions regarding action reside with DVLA.

The panel Chair noted that Mr Andrew Goodwin's and Dr Douglas Fraser's tenure had come to an end and thanked them for their excellent contributions to the panel over the last ten years. The panel Chair advised that his tenure is due to expire in April 2023.

#### 3. ACTIONS/MATTERS ARISING FROM PREVIOUS MEETING

#### i. Aortic Aneurysm

Panel agreed in the previous panel meeting that a vascular expert in endovascular intervention including Endovascular Aneurysm Repair (EVAR) and Thoracic Endovascular Aortic Repair (TEVAR) should be invited to the next Panel meeting.

In the interim, and from an operational perspective, type 1, or type 3 endoleak should disbar from group 2 licensing, but after successful EVAR (with no endoleak) panel had advised that the diameter of the aorta aneurysm surrounding the graft should not influence licensing decisions.

Dr Trevor Cleveland provided a presentation on driving and aortic aneurysms.

Dr Cleveland discussed the current standards in the Assessing Fitness To Drive (AFTD) guidance and the international variation in standards.

As a result of Dr Cleveland's presentation panel agreed that:





- following EVAR/TEVAR, type 1 and type 3 endoleak, and postoperative sac enlargement present a high risk to driving. Such features should be debarring to Group 2, and potentially to Group 1 licensing.
- consideration would be given to separate standards for abdominal and thoracic aneurysms
- consideration would be given to increasing the maximum acceptable diameter for abdominal aneurysms to 7.0 cm
- sacular aneurysms pose particular risk and require individual consideration
- clinical guidelines recommend annual imaging following EVAR/TEVAR the requirement for complying with such imaging should be incorporated into the medical standards

Panel thanked Dr Cleveland for his presentation. Dr Cleveland agreed to review draft changes in standards.

#### ii. Aortic stenosis

**Group 1:** The published AFTD standard was changed in 2021 such that all grades of symptomatic aortic stenosis were considered to be debarring. As a result of a number of queries regarding this change panel reviewed the situation and advised that mild or moderate symptomatic aortic stenosis does not require DVLA notification and may drive. Severe symptomatic aortic stenosis only requires DVLA notification should the driver's clinician consider that symptoms may impact upon safe driving.

#### Group 2:

- asymptomatic mild aortic stenosis does not require DVLA notification
- asymptomatic moderate aortic stenosis does not require DVLA notification but does require regular medical review
- asymptomatic severe aortic stenosis requires successful completion of an exercise test, at least annual clinical review, and clinician support for licensing

If exercise testing is not possible in an individual with severe asymptomatic aortic stenosis, individual assessment may be required and a cardiac MRI with Gadolinium contrast should be considered. Any late Gadolinium enhancement would be considered debarring. Individuals co-existent coronary artery disease will also require individual assessment.

DVLA thanked panel and will review the suggested changes. Currently ongoing.

### iii. Wording of Appendix C, including advice regarding functional testing





Panel reviewed the proposed revision of Appendix C. Panel agreed multiple changes need to be incorporated into a draft final version.

Panel discussed the definitions of "hypotension" and "sustained ventricular tachycardia". Hypotension was considered to be a fall in systolic blood pressure during exercise of 20mmHg or more. With regard to ventricular arrhythmia, panel advised that a successful test requires no ventricular arrhythmia resulting in either termination of the test and/or treatment of the arrhythmia.

## SECTION B: TOPICS FOR DISCUSSION

#### 4. Review Role of Fractional Flow Reserve (FFR)

Case discussion. The limitations of FFR regarding driver licensing were noted, in particular that this measurement assesses focal stenoses in individual arteries and does not assess the microcirculation. Moreover, evidence that FFR is an independent determinant of relevant clinical outcomes is limited but there is increasing evidence that non-obstructive disease may be associated with worse clinical outcome. Panel advised that CT Coronary Angiography is likely to assume an increasingly important role in future driver licensing.

# 5. Loeys-Dietz Syndrome (LDS)

LDS was previously discussed and the current AFTD standard requires individual specialist assessment for both cars and motorcycles (Group 1) and lorries and bus (Group 2) licensing. In view of the rarity of the condition and lack of panel member experience in treating the condition, Professor Maria Teresa Tome Esteban, Consultant Cardiologist, was invited to address panel.

Professor Esteban discussed the various inherited aortopathies and the risk of a disabling event while driving. Professor Esteban discussed that the spectrum of risk between the various conditions. She emphasised that the best treatment is prevention. There is a need to recognise individuals at risk and individualise driving licensing decisions beyond the aortic size. Professor Esteban advised that close clinical surveillance has resulted in such cases being addressed clinically before a situation that may pose a risk to Group 1 driving would arise.

Panel thanked Professor Esteban for her presentation. Panel also considered the letter received from Dr Fleur van Dijk, which raised similar concerns about vascular Ehlers Danlos syndrome (EDS). Panel agreed to revise the Group 1 standards for these medical conditions.

#### 6. Transient Loss of Consciousness (TLoC) – new standards

The panel Chair provided an update regarding the development of the new TLOC standards.





The panel Chair had met with the neurology panel on the 9<sup>th</sup> February 2023 to discuss the proposed changes. It was suggested that the standards for unexplained TLoC should occupy a standalone chapter in AFTD with standards for TLoC with a syncopal cause residing in the cardiovascular chapter. The standards for epilepsy would remain in the neurology chapter. It was noted that the medical conditions of cough syncope and loss of consciousness with seizure markers are not covered by the proposed new standards.

The proposed changes were discussed. A further subgroup meeting will be required to finalise the new standards.

# 7. Brugada Syndrome

To determine how to distinguish between syncope due to brugada and vasovagal syncope.

The update from Dr Rajappan was postponed until the next panel meeting due to time restraints.

#### 8. Use of Functional Testing

Panel discussed the frequency of Exercise Tolerance Testing (ETT), or its alternatives required by current Group 2 standards.

The panel Chair provided an update regarding a review of DVLA processes for commissioning functional cardiac testing. This had followed a consideration of the Ionising Radiation (Medical Exposure) Regulations (IR(ME)R and referrals for myocardial perfusion scans.

DVLA advised that the functional testing procedures have now been updated.

DVLA asked panel to consider whether the current practice of three yearly functional testing in coronary artery disease/angina should apply to all relevant Group 2 licence holders/applicants and whether there are alternative means of assessment for these medical conditions for driving purposes.

The panel Chair referred to other countries standards and the requirements of testing standards. Panel discussed the frequency and volumes of cardiac function testing and the quality of data that would be required to support changes to the medical standards. Panel advised that to identify a sub-population of group 2 drivers requiring less frequent or alternative testing would be challenging. Computed Tomography Coronary Angiography (CTCA) might have an increasing role in such decision making in the future.

DVLA advised of a meeting on the 17 March 2023 with Department of Transport's researchers with the aim of identifying the possibility of research being undertaken on behalf of the medical panels. Panel advised they looked forward to hearing the outcome of the meeting.





# SECTION C: ONGOING AGENDA ITEMS

#### 9. Tests, horizon scanning, research, and literature

DVLA reminded all panel members that as part of the Terms and Conditions they have an obligation to update panel about any information/tests/research that could impact on the medical standards or existing processes.

The panel Chair discussed the relationship of obesity to sudden cardiac death rate which may be relevant to group 2 licensing.

### 10. AOB

#### Membership update

DVLA provided a membership update on the panel composition, and informed panel that expert member recommendations had been submitted to the Minister. Panel thanked DVLA for the update and discussed induction days for new and existing panel members who have not yet had the opportunity to visit the DVLA. DVLA confirmed that an induction day would be planned in the coming months.

## 11. Date and time of next meeting

Thursday 5<sup>th</sup> October 2023

Original draft minutes prepared by: Sian Taylor

**Note Taker** 

**Date: 21st March 2023** 

Final minutes signed off by: Dr R Henderson

Chairperson

Date: 2<sup>nd</sup> May 2023

THE DVLA WILL CONSIDER THE ADVICE PROVIDED BY THE PANEL AND NO CHANGES TO STANDARDS WILL TAKE EFFECT UNTIL THE IMPACT ON INDIVIDUALS AND ROAD SAFETY IS FULLY ASSESSED.

